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Classification	 of	 acute	 lymphoblastic	 and	 myeloid	 leukemias	 (ALL	 and	 AML)	 remains	35 
heavily	 based	 on	 phenotypic	 resemblance	 to	 normal	 hematopoietic	 precursors.	 This	36 
framework	can	provide	diagnostic	challenges	for	immunophenotypically	heterogeneous	37 
immature	 leukemias,	 and	 ignores	 recent	 advances	 in	 understanding	 of	 developmental	38 
multipotency	 of	 diverse	 normal	 hematopoietic	 progenitor	 populations	 that	 are	39 
identified	 by	 transcriptional	 signatures.	 We	 performed	 transcriptional	 analyses	 of	 a	40 
large	series	of	acute	myeloid	and	lymphoid	leukemias	and	detected	significant	overlap	in	41 
gene	 expression	 between	 cases	 in	 different	 diagnostic	 categories.	 Bioinformatic	42 
classification	of	leukemias	along	a	continuum	of	hematopoietic	differentiation	identified	43 
leukemias	 at	 the	 myeloid/T-lymphoid	 interface,	 which	 shared	 gene	 expression	44 
programs	with	 a	 series	 of	multi	 or	 oligopotent	 hematopoietic	 progenitor	 populations,	45 
including	 the	 most	 immature	 CD34+CD1a-CD7-	 subset	 of	 early	 thymic	 precursors.	46 
Within	 these	 interface	 acute	 leukemias	 (IALs),	 transcriptional	 resemblance	 to	 early	47 
lymphoid	 progenitor	 populations	 and	 biphenotypic	 leukemias	 was	 more	 evident	 in	48 
cases	 originally	 diagnosed	 as	 AML,	 rather	 than	 T-ALL.	 Further	 prognostic	 analyses	49 
revealed	 that	 expression	 of	 IAL	 transcriptional	 programs	 significantly	 correlated	with	50 
poor	outcome	in	independent	AML	patient	cohorts.	Our	results	suggest	that	traditional	51 
binary	 approaches	 to	 acute	 leukemia	 categorization	 are	 reductive,	 and	 that	52 






Successful	 management	 of	 acute	 leukemia	 is	 underpinned	 by	 accurate	 diagnostic	57 
classification,	 which	 provides	 a	 basis	 for	 treatment	 allocation,	 risk	 stratification	 and	58 
implementation	 of	 targeted	 therapies	 (1).	 Although	 knowledge	 of	 the	 molecular	59 
landscape	of	 leukemia	has	 increased	enormously	over	the	past	decades,	contemporary	60 
classification	remains	heavily	predicated	on	simple	immunophenotypic	resemblance	to	61 
either	myeloid	or	lymphoid	normal	hematopoietic	precursors	(2).	While	this	system	has	62 
historically	 been	 successful,	 some	 leukemia	 categories	 provide	 specific	 diagnostic	 and	63 
therapeutic	challenges.	The	current	World	Health	Organization	(WHO)	classification	(2)	64 
recognizes	 acute	 leukemias	 of	 ambiguous	 lineage	 that	 either	 lack	 lineage-specific	65 




(T-ALL)	 and	 acute	 myeloid	 leukemia	 (AML).	 T-ALL	 can	 be	 subclassified	 by	70 
immunogenotypic	 and	 phenotypic	 resemblance	 to	 either	 immature/	 early	 thymic	71 
precursor	 (ETP),	 early	 cortical	 or	 late	 cortical	 normal	T-progenitor	 equivalents	 (6,	 7).	72 
However,	 the	 genotypic	 and	 phenotypic	 heterogeneity	 of	 immature	T-ALLs	mean	 that	73 
robust	biological	classification	of	this	group	is	not	straightforward	(8).	A	subset	of	these	74 
cases	 harbor	mutations	 that	 are	 also	 commonly	 seen	 in	 AML,	 suggesting	 that	 at	 least	75 
some	 immature	 T-ALLs	may	 arise	 from	 transformation	 of	 a	 bipotent	 lympho-myeloid	76 
progenitor	(9-13).	In	addition,	diagnostic	distinction	from	AML	by	immunophenotype	is	77 




also	 biologically	 heterogeneous	 and	 expresses	 lymphoid-associated	 antigens	 such	 as	80 
CD7	or	TdT	in	about	50%	of	cases	(15).	Immature	T-ALLs	are	frequently	chemoresistant	81 
and	require	intensive	treatment	(10,	14,	16),	while	M0-AML	cases	have	poor	outcomes	82 
compared	 to	 other	 AML	 subgroups	 (17,	 18),	 so	 it	 is	 clinically	 important	 to	 consider	83 
whether	improved	classification	of	these	cases	might	allow	better	therapeutic	choices.	84 
Current	 leukemia	 classification	 also	 takes	 little	 account	 of	 modern	 advances	 in	85 
understanding	of	human	hematopoiesis,	and	the	recognition	of	a	diverse	range	of	pluri-	86 
and	multipotent	progenitors,	 as	 identified	by	 transcriptional	 signatures	and	 functional	87 
assays	(19).	 In	particular,	 traditional	notions	of	an	early	 lymphoid/myeloid	dichotomy	88 
have	been	undermined	by	the	discovery	of	a	multitude	of	lymphoid	committed	cell	types	89 
which	 retain	 myeloid	 potential	 at	 different	 stages	 of	 differentiation:	 	 within	 the	90 





according	 to	 a	 limited	 number	 of	 expression	 signatures	 that	 correlate	 with	 the	96 
phenotype	of	differentiation	arrest	(6,	29,	30).	Data	may	also	be	interrogated	by	gene	set	97 
enrichment	 analysis	 (GSEA),	 which	 has	 revealed	 that	 immature/ETP-ALLs	98 
transcriptionally	 resemble	 both	 normal	 hematopoietic	 stem	 cell	 (HSC)	 and	 immature	99 
myeloid	precursors	(9).	However,	these	approaches	rely	on	comparisons	of	predefined	100 
sample	 groups,	 neglect	 transcriptional	 heterogeneity	 of	 individual	 leukemias	 in	 each	101 
group	 and	 cannot	 resolve	 relationships	 between	 groups.	 These	 analyses	 therefore	102 
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provide	 limited	 information	 about	 the	 spectrum	 of	 differentiation	 arrest	 in	 acute	103 
leukemia.	104 
Evolutions	 in	 genomic	 analytical	 methods	 provide	 an	 opportunity	 to	 refine	 leukemia	105 
classification.	 We	 have	 analyzed	 a	 series	 of	 acute	 leukemias	 that	 comprised	 a	 high	106 
proportion	 of	 immature	 T-ALLs	 and	 AMLs	 using	 several	 complementary	 methods.	107 
Firstly,	we	 show	 that	hierarchical	 clustering	and	dimensionality	 reduction	approaches	108 
consistently	 identify	 an	 AML-like	 subset	 of	 T-ALL.	 To	 gain	 deeper	 insight	 into	 the	109 
spectrum	of	differentiation	arrest	 in	 these	 leukemias,	we	then	used	the	novel	 Iterative	110 
Clustering	 and	 Guide	 Gene	 Selection	method	 (ICGS).	 This	 technique,	 when	 applied	 to	111 
single-cell	 RNA-sequencing	 data,	 has	 been	 shown	 to	 infer	 cellular	 states	 from	112 
transcriptional	data,	 identify	modules	of	guide	genes	 that	are	 specific	 to	 these	 cellular	113 
developmental	 states	 in	 an	 unbiased,	 agnostic	 manner,	 and	 infer	 developmental	114 
relationships	 between	 these	 states	 (31).	 We	 show	 that	 application	 of	 ICGS	 to	 global	115 
expression	data	identifies	a	continuum	of	differentiation	arrest,	which	includes	a	group	116 






Microarray	 data	 analysis:	All	 computational	 analysis	was	 performed	 in	R	 (v.3.3.2	 or	121 
above)	 unless	 otherwise	 specified.	 Data	 were	 normalised	 with	 normalize.quantiles	122 
function	 from	 the	 preprocessCore	 v1.34.0	 package	 and	 batch	 effects	 between	 2	123 





ICGS:	 ICGS	 was	 performed	 with	 AltAnalyze	 software	 v.	 2.1.0	129 
(http://www.altanalyze.org/)	 using	HOPACH	 clustering,	with	 default	 settings	 for	 gene	130 
expression	 analysis	 options	 (moderated	 t-test	 for	 group	 comparison	 and	 Benjamini-	131 
Hochberg	false	discovery	rate	<0.05).	The	gene	expression	filtering	option	was	set	to	2.			132 





limma	 package	 (lmFit	 function)	 for	 microarray	 and	 DESeq2	 for	 RNA-Seq.	 	 	 Contrast	138 
matrices	 between	 selected	 groups	 are	 listed	 in	 Supplementary	 Table	 S1.	 Genes	 were	139 
considered	 differentially	 expressed	 if	 Benjamini-Hochberg	 false	 discovery	 rate	140 
(FDR) < 0.05.	 	 Gene	 ranking	 for	 Gene	 Set	 Enrichment	 Analyis	 (GSEA)	 was	 performed	141 




as	 the	 union	 of	 all	 the	 probes	 differentially	 expressed	 between	 any	 two	 populations	144 
(thymic	HVGs,	8751	probes).		145 
Pathway	and	Gene	Set	Enrichment	Analysis:	GSEA	was	performed	with	GSEA	software	146 
(http://software.broadinstitute.org/gsea/index.jsp)	 using	 the	 C2.all.v6.1	 collection	 of	147 
genesets	from	MSigDB	(http://software.broadinstitute.org/gsea/msigdb/index.jsp)	or	a	148 
collection	 of	 custom	 genesets	 (Supplementary	 Table	 S1)	 derived	 from	 datasets	149 
generated	 here	 or	 publicly	 available	 (19,	 23,	 24,	 34-36).	When	 specific	 genesets	were	150 




FDR<0.05)	were	 selected	as	 genesets	 to	be	 tested	by	GSEA.	GSEA	outputs	were	either	155 
visualised	 with	 the	 EnrichmentMap	 plugin	 (FDR	 Q-value	 cutoff	 0.05)	 of	 Cytoscape	156 
(v.3.2.0),	 or	with	 heatmaps	 generated	with	 Prism	 software	 (v.7).	 ClueGO	 analysis	was	157 









leukemias	 (See	 Supplementary	 Methods).	 In	 order	 to	 maximize	 our	 ability	 to	 detect	165 
shared	 patterns	 of	 gene	 expression	 in	 immature	 leukemias,	 the	 study	 cohort	 was	166 
intentionally	 skewed	 to	 include	 a	 higher	 proportion	 of	 these	 cases	 than	 would	 be	167 
observed	 by	 chance.	 26/48	 T-ALLs	 (54.2%)	 had	 an	 immature	 T-receptor	168 
immunogenotype	 (37),	 comprising	 9	 IM0	 (germline	 TR),	 9	 IMD	 (TRD	 rearrangement	169 






in	 the	AML	cluster	 in	 this	unsupervised	analysis,	and	clustered	 together	when	HC	was	176 
restricted	 to	 T-ALLs	 (Supplementary	 Figure	 S1A).	 When	 visualized	 by	 Principal	177 
Component	Analysis	(PCA),	T-ALL	and	AML	samples	were	distributed	differently	along	178 
the	 first	 principal	 component.	 Notably,	 T-ALL	 samples	 clustering	 with	 AMLs	 by	 HC	179 
overlapped	with	AML	samples	(Supplementary	Figure	1B).		180 
Not	all	of	 these	AML-like	T-ALLs	exhibited	 immunogenotypic	 immaturity	 (6/8)	or	had	181 





AML-like	 T-ALLs	 are	 enriched	 for	 immature	 myeloid	 and	 thymic	 progenitor	185 
transcriptional	signatures	186 
We	next	examined	the	transcriptional	differences	between	AML-like	cases	and	the	rest	187 
of	 the	 T-ALL	 cohort.	 2274	 genes	 (Supplementary	 Table	 S3)	 were	 significantly	188 
differentially	 expressed	 between	 the	 groups	 (FDR	 <0.05),	 with	 1213	 and	 1061	189 
respectively	 upregulated	 and	 downregulated	 in	 AML-like	 T-ALLs.	 Pathway	 analysis	190 
revealed	 that	AML-like	T-ALLs	had	elevated	expression	of	 genes	 involved	 in	 cell	 cycle	191 
and	mitochondrial,	amino-acid	and	pyruvate	metabolism,	and	high	levels	of	interferon-192 
related	genes,	MYC,	HOXA,	MEIS1	and	GATA2	targets	 (Figure	1B).	Gene-sets	 that	were	193 
previously	 reported	 to	 be	 upregulated	 in	 AML	 in	 independent	 datasets	 were	 also	194 
significantly	 over-represented.	 In	 contrast,	 TCR,	 NOTCH1	 and	 TNF	 signaling	 were	 all	195 
downregulated.		196 
We	 then	 sought	 to	better	 characterize	AML-like	T-ALLs	 similarity	 to	normal	 stem	and	197 
progenitor	 cells,	 firstly	 by	 performing	GSEA	 using	 normal	 umbilical	 cord	 blood	 (UCB)	198 
hematopoietic	 progenitor	 transcriptional	 signatures	 that	we	previously	 reported	 (38).	199 
AML-like	 T-ALLs	were	 significantly	 enriched	 for	megakaryocytic-erythroid	 progenitor	200 
(MEP)	 and	 granulocyte-monocyte	 progenitor	 (GMP),	 but	 not	 hematopoietic	 stem	 cells	201 
(HSC)	 signatures.	 These	 leukemias	 were	 also	 enriched	 for	 a	 GMP	 signature	 from	 an	202 
independent	 data-set	 (23),	 and	 resembled	 lymphoid-mono-dendritic	 progenitors	203 
(LMDP)	from	an	UCB-derived	humanized	murine	model	of	early	lymphoid	development	204 
(24)	 (Figure	 1C).	 To	 confirm	 transcriptional	 similarity	 to	 myeloid	 progenitors,	 we	205 
combined	 the	 gene	 expression	of	 the	T-ALL	 samples	with	 that	 of	 highly	purified	 stem	206 




We	 then	performed	 transcriptional	 profiling	 of	 six	 phenotypically	 defined	T-lymphoid	209 
progenitor	 groups	 isolated	 from	 a	 series	 of	 human	 thymuses	 (Supplementary	 Figure	210 
S2A).	 The	 genes	most	 differentially	 expressed	 in	 each	 subpopulation	 (Supplementary	211 
Figure	S2B	and	Supplementary	Table	S4)	were	consistent	with	known	T-lymphopoietic	212 
transcriptional	 patterns.	 PCA	 also	 reflected	 this	 developmental	 progression	213 








subsets.	 Strikingly,	 AML-like	 T-ALLs	 were	 strongly	 positively	 enriched	 for	 genes	 that	222 
were	 specifically	 expressed	 by	 the	 most	 immature	 CD34+CD1a-CD7-	 thymic	223 
subpopulation	(Figure	1C).	Of	note,	this	signature	differed	from	an	ETP	transcriptional	224 
profile	that	we	previously	reported,	which	was	derived	by	comparison	to	CB	stem	and	225 
progenitor	 cells	 (38)	 (Supplemental	 Figure	 2E-2G).	 	Conversely,	when	 compared	with	226 
the	rest	of	the	T-ALL	cohort,	AML-like	T-ALL	samples	were	negatively	enriched	for	‘late’	227 
thymic	 discriminating	 genes	 (Figure	 1C).	 Taken	 together,	 these	 results	 indicate	 that	228 
AML-like	 T-ALLs	 share	 gene	 expression	 programs	 with	 both	 UCB-derived	 myeloid-229 




Iterative	 Clustering	 and	 Guide	 Gene	 Selection	 analysis	 identifies	 a	 continuum	 of	232 
leukemic	differentiation	arrest		233 
We	next	 sought	 to	 gain	 a	 deeper	 insight	 into	 the	 spectrum	of	 differentiation	 arrest	 in	234 
these	 acute	 leukemias,	 by	 using	 the	 recently	 described	 ICGS	 method.	 This	 analysis	235 
employs	serial	 iterative	clustering	with	pattern-specific	guide	genes	to	define	coherent	236 
transcriptional	patterns	between	 samples	and	 then	groups	 these	 samples	 into	 cellular	237 
states	that	recapitulate	developmental	trajectories	(31).	238 
To	 test	 the	 feasibility	of	applying	 this	approach	 to	 leukemic	datasets,	we	 initially	used	239 
ICGS	 to	analyze	 two	published	 series	of	 adult	 (33)	and	pediatric	 (32)	T-ALL.	For	both	240 
cohorts,	 the	 ICGS	 algorithm	 unbiasedly	 identified	 guide	 gene	 modules	 enriched	 for	241 
human	 stem	 and	 progenitor	 cells	 (HSPCs,	 CD34+),	 myeloid	 cells	 and	 thymocytes	242 
(Supplementary	Figure	S3A	and	S3C	and	Supplementary	Table	S5),	and	ordered	the	T-243 




(32),	 ICGS	 ordering	 recapitulated	 in	 an	 unsupervised	 manner	 the	 classification	 the	248 
authors	had	derived	linking	mutations	to	thymic	developmental	stages	(Supplementary	249 
Figure	 S3C	 and	 S3D).	 	We	 thus	 concluded	 that	 ICGS	 allows	 unbiased	 classification	 of	250 
leukemic	samples	according	to	their	stage	of	differentiation	arrest.	251 
We	 then	used	 ICGS	 to	 analyze	our	patient	 cohort.	 ICGS	 classified	 these	 leukemias	 into	252 
five	 developmental	 clusters	 that	were	 defined	 by	 the	 levels	 of	 expression	 of	 a	 limited	253 
number	 of	 guide	 genes	 (Figure	 2A	 and	 Supplementary	 Table	 S5)	 that	 again	254 
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predominantly	 comprised	 transcripts	 that	 discriminate	 hematopoietic	 cell	 types.	 The	255 
proportions	of	different	 leukemic	phenotypes	within	each	cluster	are	 shown	 in	Figure	256 
2B.	Cluster	1	was	defined	by	high	expression	of	thymic-	and	lymphoid-related	genes	(e.g.	257 
TCF7,	LCK,	BCL11B),	and	comprised	T-ALL	cases	exclusively.	Conversely,	Clusters	4	and	258 
5	were	 effectively	 restricted	 to	 AML	 cases,	with	 concentration	 of	 Core	Binding	 Factor	259 
(CBF)-AMLs	 in	 cluster	5.	 These	 clusters	 exhibited	 increased	 expression	of	 factors	 that	260 
define	 myeloid	 transcriptional	 modules	 (e.g.	 MPO,	 CEBPE,	 CSF3R).	 The	 intermediate	261 
Clusters	 2	 and	 3	 were	 characterized	 by	 heterogeneous	 guide	 gene	 expression,	 and	262 
included	 one	 third	 of	 T-ALL	 cases	 (16/48,	 33.3%).	 Notably,	 the	 most	 immature	 M0	263 
subtype	 AMLs	 were	 predominantly	 found	 in	 these	 two	 clusters	 (24/28,	 85.7%),	 as	264 
compared	with	14/48	(29.2%,	p<0.001	by	Fisher	test)	of	non-M0-AML.	Also,	virtually	all	265 
AML-like	 T-ALL	 samples	 that	 were	 defined	 by	 HC	 (7/8,	 87.5%)	were	 found	 in	 either	266 
Cluster	 2	 (n=4)	 or	 3	 (n=3).	 ICGS	 therefore	 provides	 a	means	 of	 classifying	 leukemias	267 
along	a	spectrum	of	hematopoietic	ontogeny,	which	in	our	cohort	included	a	significant	268 
number	 of	 cases	 at	 the	 interface	 between	 T-lymphoid	 and	myeloid	 lineages.	 Broadly,	269 
these	 ‘interface’	 acute	 leukemias	 (IAL)	 either	 showed	 no	 clear	 evidence	 of	mature	 T-270 
lymphoid	or	mature	myeloid	identity	(Cluster	2),	or	had	a	partial	HSPC/mature	myeloid	271 
signature	(Cluster	3).	272 








mutation	 patterns.	 For	 example,	 Cluster	 1	 was	 enriched	 both	 for	 T-ALL	 type	 NOTCH	279 
pathway-activating	 mutations	 (p<0.0001,	 all	 comparisons	 by	 Fisher	 test)	 and	 for	280 
mutations	that	are	more	frequent	in	immature	T-ALLs	(9,	10,	40),	e.g.	SUZ12	(p=0.004),	281 
WT1	(p=0.0044)	and	IL7R/JAK/STAT	pathway	members	(p=0.0364).	282 
Similarly,	 interface	 clusters	 were	 enriched	 for	 alterations	 in	 DNA	methylating	 factors	283 






Having	 found	 that	 ICGS	 permits	 classification	 of	 acute	 leukemias	 along	 a	 spectrum	 of	290 





Within	 our	 cohort,	 Cluster	 1	 T-ALLs	were	 strongly	 enriched	 for	mid-	 and	 late-thymic	296 
expression	 profiles,	 and	 negatively	 enriched	 for	 both	 early	 thymic	 and	 UCB	 HSC	 and	297 
myeloid	progenitor	signatures.	AMLs	in	Clusters	4	and	5	had	broadly	converse	patterns	298 
of	positive	and	negative	enrichment	(Figure	3A).	299 
Transcriptional	 differences	 in	 IAL	Clusters	 2	 and	3	were	 less	 clear-cut.	 Cluster	 2	 IALs	300 
were	enriched	 for	both	HSC	and	a	 series	of	 lymphoid	progenitor	 signatures,	 including	301 
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MLP,	 LMDP,	 early	 B-cell	 progenitors,	 T-oriented	 CD127-	 Early	 Lymphoid	 Precursors	302 
(ELPs)	 and	CD34+CD1a-CD7-	 early	 thymic	 cells	 (Figure	 3A).	 Cluster	 3	 IAL	 cases	were	303 
more	 likely	 to	be	enriched	 for	myeloid	profiles	 (MEP,	GMP	and	UC-derived	monocyte-304 
dendritic	 cell	 progenitors,	 MDCP),	 but	 also	 showed	 transcriptional	 resemblance	 to	305 
several	 lymphoid	 subpopulations,	 including	 LMDP	 and	 both	 early	 and	 mid-thymic	306 
signatures	(Figure	3A).		307 
We	considered	whether	this	heterogeneity	might	be	driven	by	differing	transcriptional	308 
contributions	 of	 T-ALLs	 and	 AMLs	 within	 each	 cluster.	 Further	 analysis	 of	 Cluster	 2	309 
revealed	 the	surprising	 finding	 that	while	T-ALLs	were	mostly	negatively	enriched	 for	310 
lymphoid	 signatures,	AMLs	had	expression	patterns	 that	 resembled	 several	 lymphoid-311 
competent	 populations,	 including	 MLPs,	 T-oriented	 CD127-	 and	 B-oriented	 CD127+	312 
ELPs	 and	 early	 B-cell	 progenitors	 (Figure	 3B).	 Similarly,	 Cluster	 3	 AMLs	 showed	313 
significant	enrichment	 for	LMDP	and	mid-thymic	signatures,	while	T-ALLs	 in	the	same	314 
group	were	more	 likely	 to	 resemble	myeloid	populations,	 including	GMPs	 and	MDCPs	315 
(Figure	3C).	These	data	 suggest	 that	 interface	AMLs	demonstrate	 significant	 lymphoid	316 
orientation,	which	can	be	more	pronounced	than	the	T-ALLs	with	which	they	co-cluster	317 








leukemic	 stem	 cell	 (LSC)	 transcriptional	 signature	 (34),	 and	 that	 this	 enrichment	was	324 
shared	by	both	T-ALLs	and	AMLs	 in	this	group	(Figures	3E	and	3F).	AMLs	 in	 interface	325 
Cluster	 3	 (Figure	 3G),	 and	 AML-like	 T-ALLs	 (NES=1.92;	 FWER=0.003)	 were	 also	326 
enriched	for	the	LSC	signature,	suggesting	that	expression	of	leukemia	stemness	genes	is	327 
a	common	feature	of	IAL	cases.		328 
As	 interface	 leukemias	 share	 expression	 profiles	 with	 a	 range	 of	 progenitors	 of	329 
multipotent	 lineage	 capacity,	 we	 next	 tested	 whether	 there	 was	 any	 transcriptional	330 
similarity	to	MPALs	of	either	T-lymphoid/myeloid	(T/M	MPAL)	or	B-lymphoid/	myeloid	331 
(B/M	 MPAL)	 phenotype	 in	 children	 (35)	 and	 adults	 (36).	 We	 found	 that	 interface	332 
Clusters	2	and	3	were	enriched	for	B/M	MPAL	and	T/M	MPAL	signatures	respectively,	333 
and	 that	enrichment	was	driven	by	 the	AML	cases	 in	each	group	(Figures	3F	and	3G).	334 






affect	 clinical	 behavior.	We	 therefore	 evaluated	 the	outcome	of	 interface	AMLs	 in	 two	341 
independent	 studies	 (44,	 45).	 To	 identify	 these	 cases,	we	 calculated	 an	 interface	AML	342 
(IAL)	 score	based	on	gene	expression	differences	between	 interface	and	non-interface	343 
AMLs	 in	 our	 cohort	 (Supplementary	Methods	 and	 Supplementary	 Table	 S8).	 Outcome	344 
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analyses	 revealed	 that	AMLs	with	high	 IAL	scores	had	significantly	 shorter	 survival	 in	345 
both	 studies	 (Figures	 4A	 and	 4B).	 Within	 the	 ALFA-1701	 group,	 these	 effects	 were	346 





score	 predicted	 outcome	 independently	 of	 other	 prognostic	 variables,	 including	352 
cytogenetic	classification,	ELN	subgroups	and	 the	recently-described	LSC17	score	 (34)	353 
(Table	1).	Consistent	with	this,	our	IAL	signature	had	almost	no	overlap	with	the	LSC17	354 
signature,	or	the	extended	48	gene	signature	that	was	reported	in	the	same	paper	(34)	355 
(Supplementary	 Figure	 S4A	 and	 S4B).	 Full	 comparison	 of	 clinicobiological	 and	356 
mutational	 profiles	 of	 ALFA-0701	 patients	 with	 high	 and	 low	 IAL	 scores	 is	 shown	 in	357 
Supplementary	 Table	 S10.	 Finally,	 we	 evaluated	 whether	 high	 IAL	 score	 cases	 had	358 
evidence	 of	 lymphoid	 transcriptional	 activation.	 In	 keeping	 with	 our	 earlier	 results	359 
(Figure	3),	we	 found	 that	high	 IAL	score	cases	 in	both	AML	cohorts	were	significantly	360 






In	 keeping	 with	 modern	 concepts	 of	 a	 hematopoietic	 progenitor	 framework	 that	365 
comprises	a	spectrum	of	differentiation	potential,	integrated	transcriptional	analysis	of	366 
AMLs	and	T-ALLs	revealed	a	continuum	of	leukemic	developmental	arrest.	While	AMLs	367 
and	 T-ALLs	 at	 either	 end	 of	 the	 spectrum	 were	 specifically	 enriched	 for	 the	368 
transcriptional	 signatures	 of	 the	 corresponding	 lineage,	 interface	 leukemias	 had	369 
evidence	of	both	myeloid	and	lymphoid	precursor	gene	expression,	with	early	lymphoid	370 
signature	enrichment	being	driven	by	 interface	AML	cases.	Specifically,	while	 interface	371 





be	more	 likely	 to	 arise	 from	 lymphoid-oriented	 progenitors	 and/or	 be	 arrested	 at	 an	377 
early	 stage	 of	 lymphoid	 orientation	 (prior	 to	 CD19	 expression)	 than	 is	 currently	378 
recognized.	 It	 should	 also	 be	 noted	 that	 the	 high	 proportion	 of	 IALs	 in	 this	 cohort	379 
reflects	 our	 deliberate	 selection	 of	 high	 proportions	 of	 immature	 leukemias,	 which	380 
exceed	what	is	seen	in	routine	clinical	practice.	381 
ICGS	 clustering	 presented	 several	 important	 differences	with	 accepted	methods	 of	 T-382 
ALL	categorization	by	phenotype,	immunogenotype	or	mutational	profile	(9,	14,	37).	For	383 
example,	 the	majority	of	 immature	T-ALLs	defined	by	TR	 rearrangement	 (37)	 (16/26,	384 
61.5%)	 or	 ETP-ALL	 phenotype	 (12/20,	 60%)	 (14)	 were	 in	 Cluster	 1,	 including	 those	385 
with	JAK-STAT	pathway	mutations	(Supplementary	Table	S7).	In	addition,	IALs	had	low	386 





mutations	 were	 always	 accompanied	 by	NOTCH1	 alterations	 in	 Cluster	 1,	 3/5	 PHF6-390 
mutated	IALs	(1/3	T-ALL	and	2/2	AML)	were	NOTCH1	wild-type.	This	pattern	was	also	391 
reported	in	MPAL	(35,	49),	and	suggests	that	the	leukemic	phenotype	of	PHF6	mutation	392 
may	 correlate	 with	 co-expression	 of	 other	 oncogenes,	 as	 shown	 for	 TLX3	 (50).	393 
Interestingly,	PHF6	has	been	shown	to	regulate	B/T	lineage	plasticity,	at	least	on	a	BCR-394 
ABL	 leukemic	 background	 (51).	 Interface	 AMLs	 were	 also	 not	 restricted	 to	395 
immunophenotypically	immature	M0	cases,	since	they	included	29%	of	non-M0	AMLs.		396 
Our	description	of	myeloid/T-lymphoid	 IALs	provides	 support	 for	 recent	proposals	 to	397 
define	 acute	myeloid/T-lymphoblastic	 leukemia	 (AMTL)	 as	 a	distinct	diagnostic	 entity	398 
(11),	 but	our	 results	 also	 indicate	 that	 this	 group	 comprises	 significant	molecular	 and	399 
lineage	 heterogeneity,	 particularly	 with	 regard	 to	 lymphoid	 gene	 expression.	 When	400 
applied	to	independent	studies,	our	IAL	score	identified	AMLs	with	similar	enrichment	401 
for	 immature	 B-lymphoid	 signatures	 as	 interface	 cases	 in	 our	 cohort.	 While	 the	 IAL	402 
score	 was	 not	 designed	 to	 predict	 prognosis,	 it	 is	 striking	 that	 these	 transcriptional	403 
patterns	 correlated	 with	 poor	 response	 to	 AML	 treatment	 regimens.	 RUNX1-mutated	404 
AML-M0	 cases	 in	 our	 cohort	 showed	 B-lymphoid	 identity,	 which	 is	 consistent	 with	405 
previous	reports	(47).	Intriguingly,	RUNX1-mutated	AMLs	have	recently	been	shown	to	406 
be	 sensitive	 to	 glucocorticoids	 (52),	 which	 form	 the	 backbone	 of	 ALL	 induction	407 
treatment.	Our	findings	therefore	suggest	that	the	poor	response	of	these	cases	to	AML	408 
therapy	 in	both	adults	 (53)	 and	 children	 (54)	might	be	 improved	by	better	 treatment	409 
allocation,	 and	 would	 plead	 against	 the	 recent	 provisional	 classification	 of	 RUNX1-410 
mutated	AML-M0	with	AML	 (2).	 Finally,	we	 hope	 that	 these	 data	will	 provide	 further	411 
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Covariates	 selected	 for	 multivariate	 analyses	 were	 selected	 based	 on	 the	 results	 of	618 
univariate	analyses	(full	results	in	Supplementary	Table	S11),	with	additional	retention	619 
of	 GO	 (gemtuzumab	 ozogamicin)	 treatment	 arm.	 #According	 to	 the	 ELN-2010	620 
classification	(56)	that	was	in	use	during	the	ALFA-0701	trial,	both	Intermediate-1	and	621 









HR	 95%	CI	 p	 		 HR	 95%	CI	 p	
GO	Arm	 0.82	 0.61-1.10	 0.19	
	
0.85	 0.59-1.22	 0.38	
ELN	Risk#	 2.19	 1.71-2.80	 <0.001	
	
1.96	 1.35-2.75	 <0.001	
High	LSC17	score*	 2.45	 1.71-3.53	 <0.001	 	 1.80	 1.19-2.71	 0.005	
NPM1	mutation	 0.67	 0.48-0.94	 0.019	
	
1.47	 0.91-2.40	 0.12	






Figure	 1:	 Transcriptional	 profiling	 identifies	 AML-like	 T-ALLs	 that	 are	 enriched	628 
for	 immature	 myeloid	 and	 thymic	 progenitor	 transcriptional	 signatures.	 (A)	629 
Unsupervised	 hierarchical	 clustering	 (HC)	 of	 the	 transcriptional	 profiles	 of	 124	 acute	630 
leukemias,	comprising	48	T-ALLs	and	76	AMLs.	A	subset	of	T-ALL	cases	segregates	with	631 




derived	 from	 the	 indicated	 published	 datasets	 or	 our	 own	 analysis	 of	 thymic	636 
subpopulations	(gene-sets	provided	in	Supplementary	Table	S1)	in	AML-like	T-ALLs	by	637 
GSEA.	NES	 =	Normalized	 Enrichment	 Score,	 crossed	 out	 boxes	 indicate	 gene-sets	 that	638 
are	 not	 significantly	 enriched	 (FDR	 >	 0.05).	 HSC	 =	 Hematopoietic	 Stem	 Cell,	 CMP	 =	639 
Common	 Myeloid	 Progenitor,	 GMP	 =	 Granulocyte-Monocyte	 Progenitor,	 MEP	 =	640 
Megakaryocytic-Erythroid	 Progenitor,	 MLP	 =	 Multi-Lymphoid	 Progenitor,	 LMPP	 =	641 
Lymphoid-Primed	Multipotent	Progenitor,	MDCP	=	Monocyte-Dendritic	cell	Progenitor,	642 
LMDP	=	Lymphoid-Mono-Dendritic	Progenitor,	ELP	=	Early	Lymphoid	Precursor.	(D)	2D	643 
PCA	 map	 of	 umbilical	 cord	 blood	 stem	 and	 progenitor	 populations	 and	 T-ALL	 gene	644 
expression	patterns		(38);	distribution	of	AML-like	T-ALLs	(blue	squares)	is	significantly	645 





continuum	 of	 leukemic	 differentiation	 arrest.	 (A-B)	 ICGS	 analysis	 of	 adult	 and	649 
pediatric	T-ALLs	(n=48	samples)	and	AMLs	(n=76	samples)	identifies	5	acute	leukemia	650 
clusters	 (top).	 (A)	 	 Heatmap	 of	 expression	 of	 guide	 genes	 selected	 by	 ICGS.	 Columns	651 
represent	 individual	 samples.	 Bars	 on	 the	 top	 identify	 ICGS	 clusters.	 Rows	 represent	652 
genes,	and	bars	on	the	side	represent	blocks	of	correlated	genes.	Selected	enriched	gene	653 
ontology	 groups	 are	 shown.	 Full	 gene	 lists	 are	 provided	 in	 Supplementary	 Table	 S5.	654 
Leukemic	phenotypes	are	 indicated	 in	the	bars	below	the	heatmap.	(B)	Proportions	of	655 
leukemic	 phenotypic	 groups	 in	 each	 ICGS	 cluster.	 (C)	 Mutations	 observed	 in	 T-ALL	656 
(n=34)	 and	 AML	 (n=45)	 samples	 ordered	 according	 to	 ICGS	 analysis	 in	 (A).	 Only	657 
mutations	found	in	at	least	2	samples	are	shown.			658 
	659 
Figure	 3:	 Transcriptional	 characterization	 of	 ICGS-defined	 clusters.	 GSEAs	 using	660 






transcriptional	 signatures	 by	 GSEA	 of	 (E)	 all	 clusters,	 (F)	 interface	 cluster	 2	 and	 (G)	667 







(45).	 OS	 =	 Overall	 Survival.	 EFS	 =	 Event-free	 Survival.	 Hazard	 ratios	 (HR)	 and	 95%	673 
Confidence	 Intervals	 for	 each	 event	 and	 p	 values	 are	 indicated.	 	 (C)	 Outcome	674 
comparisons	according	to	IAL	score	and	treatment	with	gemtuzumab	ozogamicin	(GO)	675 
in	the	ALFA-1701	cohort.	(D)	Comparison	of	CD33	expression	in	IAL	High	and	Low	cases	676 
in	 the	ALFA-1701	cohort.	Boxes	 indicate	median,	 interquartile	range	and	whiskers	 the	677 
95	percentile.		678 
